Product Description
IMD101 (IL-2 TMEAkine) is a fully masked IL-2 that can be re-activated into a fully active IL-2 molecule in the tumor microenvironment, showing excellent safety and therapeutic effects; IMD101 is designed essentially different from the receptor-selective IL-2, and is planned to launch clinical trials in multiple cancers including bladder cancer, lymphoma, liver cancer, and melanoma. In the future, next generation drugs that are specifically designed to be activated by the tumor microenvironment such as chemotherapy, immunotherapy and ADC drugs could participate in various combined anticancer treatments due to their low toxicity. (Sourced from: http://www.affinitybiopharma.com/en/newsD-500.html)
Mechanisms of Action: IL2 Inhibitor
Novel Mechanism: No
Modality: Cytokine
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Catalysis Therapeutics Pty Ltd
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Bladder Cancer|Kidney Cancer|Melanoma|Mesothelioma|Non-Small-Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| None | P1 |
Not yet recruiting |
Bladder Cancer|Melanoma|Non-Small-Cell Lung Cancer|Kidney Cancer|Mesothelioma |
2025-11-28 |